Open access
Methodological insights and clinical outcomes in ALS and FTLD: lessons from the SPIN cohort
Á. Carbayo
J. Turon-Sans
D. Alcolea
E. Cortés‐Vicente
Manuel Cabezas-Torres
Esther Alvarez-Sanchez
L. Muñoz
S. Rubio-Guerra
J. García-Castro
J. Selma-González
Sara Bernal
L. González-Quereda
A. Bejanin
M. Aranha
M. Santos-Santos
O. Belbin
Ana Vesperinas-Castro
R. Collet-Vidiella
M. Caballero-Ávila
L. Llansó
L. Querol
A. Lleó
J. Fortea
E. Gelpi
O. Dols-Icardo
I. Illán-Gala
Ricard Rojas-García
Medicine
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) constitute a clinico‐genetic‐neuropathological continuum with marked heterogeneity. Reliable in vivo biomarkers of the disease are lacking. Large, multimodal cohorts are needed to advance biomarker discovery and precision medicine.